On June 2, 2023 AskGene Pharma Inc. reported its participation in the prestigious 15th International Gastric Cancer Congress (IGCC 2023), scheduled to take place on June 14-17, 2023 in Yokohama, Japan (Press release, AskGene Pharmaceuticals, JUN 2, 2023, View Source [SID1234632384]). At the conference, AskGene will give an oral presentation on the latest clinical results of NCT04632108 for ASKB589, an anti-CLDN18.2 antibody, on June 16, 2023. The presenter will be the leading principal investigator Dr. Lin Shen, professor from Peking University Cancer Hospital.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IGCC is a world renowned biennial global academic conference sponsored by the International Gastric Cancer Association (IGCA). IGCC 2023 will be a hybrid online/offline conference.
Presentation Details
Title: A phase I/II study of ASKB589 (Anti-Claudin 18.2 (CLDN18.2) monoclonal antibody) in patients with solid tumors
Session: Oral 26 – Clinical Study
Date and Time: Friday, June 16, 2023 16:50-17:22 Local Time
Abstract Number: 01074
Leading PI: Dr. Lin Shen, professor from Peking University Cancer Hospital.
About NCT04632108
The NCT04632108 study is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of ASKB589 as a monotherapy and in a combination chemotherapy in patients with advanced solid tumors. The study includes ASKB589 monotherapy dose escalation and expansion (Part A) and dose escalation and expansion of ASKB589 combined with CAPOX (capecitabine and oxaliplatin) (Part B). Patients in the dose escalation were enrolled regardless of the expression of CLDN18.2, while patients in the dose expansion were only enrolled if their tumors tested positive for CLDN18.2 by a central laboratory assay. Enrollment in dose escalation for ASKB589 as monotherapy and in combination with CAPOX chemotherapy was completed in 2022. Enrollment continues in expansion cohorts of first-line advanced or metastatic patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma that is being treated with ASKB589 in combination with chemotherapy.
About ASKB589
ASKB589 is an innovative biological drug discovered and developed by AskGene. It is a recombinant humanized monoclonal antibody targeting claudin 18.2. The drug mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) through high-affinity binding to cancer cells. In addition to gastric and gastroesophageal junction cancers, ASKB589 is being tested in clinical trials for other ClDN18.2-positive solid tumors such as pancreatic cancer. A pivotal Phase III study of ASKB589 in the treatment of gastric cancer is being planned.